Catalyst
Slingshot members are tracking this event:
Top-line results of Phase 3 long-term safety and tolerability study ETC-1002-040 of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins expected in Q2 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ESPR | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 07, 2018
Occurred Source:
http://investor.esperion.com/releasedetail.cfm?ReleaseID=1059993
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ldl-c, Cholesterol Lowering, Etc-1002, Acl-inhibiting Regimen, Clear, Bempedoic Acid, Hyperlipidemia
